Oncotarget

Research Papers:

CASP8 -652 6N insertion/deletion polymorphism and overall cancer risk: evidence from 49 studies

Jiarong Cai, Qingjian Ye, Suling Luo, Ze Zhuang, Kui He, Zhen-Jian Zhuo, Xiaochun Wan and Juan Cheng _

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2017; 8:56780-56790. https://doi.org/10.18632/oncotarget.18187

Metrics: PDF 1878 views  |   HTML 2244 views  |   ?  


Abstract

Jiarong Cai1,*, Qingjian Ye2,*, Suling Luo3,*, Ze Zhuang4, Kui He5, Zhen-Jian Zhuo6, Xiaochun Wan7,8 and Juan Cheng2

1Department of Urology, The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou 510630, China

2Department of Gynecology, The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou 510630, China

3Department of Otolaryngology, The First People’s Hospital of Foshan (Affiliated Foshan Hospital of Sun Yat-Sen University), Foshan 528000, China

4Department of Joint Surgery and Orthopaedic Trauma, The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou 510630, China

5The Second People’s Hospital of FuTian District, Shenzhen 518000, China

6School of Chinese Medicine, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong 999077, China

7Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai 200032, China

8Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China

*These authors have contributed equally to this work

Correspondence to:

Juan Cheng, email: [email protected]

Xiaochun Wan, email: [email protected]

Keywords: CASP8, -652 6N insertion/deletion, polymorphism, cancer risk, meta-analysis

Received: March 13, 2017     Accepted: April 24, 2017     Published: May 25, 2017

ABSTRACT

The CASP8 -652 6N insertion/deletion (I/D) polymorphism reduces expression of caspase 8. We conducted a meta-analysis to clarify the relationship between this polymorphism and cancer risk. Eligible articles were retrieved from PubMed, EMBASE, CNKI, and WANFANG databases through February 2017. A total of 33 articles with 49 studies, including 33,494 cases and 36,397 controls, were analyzed. We found that the CASP8 -652 6N ins/del polymorphism was associated with decreased overall cancer risk in five genetic models [DD vs. II: odds ratio (OR)=0.76, 95% confidence interval (CI)=0.69–0.84, ID vs. II: OR=0.87, 95% CI=0.83–0.92, DD vs. ID/II: OR=0.82, 95% CI=0.75–0.89, ID/DD vs. II: OR=0.85, 95% CI=0.80–0.90, and D vs. I: OR=0.87, 95% CI=0.83–0.91]. Stratified analyses showed that the polymorphism was associated with decreased risk of colorectal, breast, esophageal, renal cell, lung, cervical, bladder, gastric, and other cancers. Overall cancer risk was reduced in Asian and Caucasian patients, both hospital- and population-based studies, and both high and low quality studies. Our results highlight the role of the CASP8 -652 6N ins/del polymorphism in decreasing cancer risk. Further studies with large-cohort populations, especially for specific cancer types and ethnic groups, are needed to confirm our findings.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 18187